Paragon 28, Inc Announces Proposed Public Offering of Common Stock

JMP Securities and Needham & Company are acting as co-managers. BofA Securities and Piper Sandler & Co. are acting as joint book-running managers for the offering. Canaccord Genuity is acting as a lead manager for the offering. JMP Securities, a Citizens Company, and Needham & Company are acting as co-managers for the offering.

From the onset, Paragon 28 has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics. Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments.

FAQs for Paragon 28 Inc Stock

Paragon 28 updated its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $214.00 million-$218.00 million, compared to the consensus revenue estimate of $217.44 million. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. Paragon 28’s stock is owned by a variety of institutional and retail investors.

• BofA Securities and Piper Sandler & Co. are acting as joint book-running managers for the offering.
• Upgrade to MarketBeat All Access to add more stocks to your watchlist.
• While the Paragon group was formed in 1985, it only launched as a full bank in 2014.
• We are very pleased that the FDA has recognized the potential benefits of expanding access of this technology to more ankle patients, and we are excited to get this IDE study underway.

Paragon offers online banking through its website, but does not have a dedicated mobile app. Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise. BofA Securities and Piper Sandler are acting as joint lead book-running managers for the offering.

NYSE: FNA

We update our data regularly, but information can change between updates. Confirm details with the provider you’re interested in before making a decision. Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of FNA stock can currently be purchased for approximately $13.76.

With approval of the IDE to support future regulatory applications, the company s SMART Total Talus is on the path to become the only device on the market intended for talar replacement in the setting of adjacent joint arthritis. Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship https://1investing.in/ between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. Several customers in our survey commented positively on Paragon’s customer service. However several customers felt that Paragon’s interest rates could be better.

Stephens Sticks to Their Buy Rating for Paragon 28 (FNA)

These statements include statements regarding a public offering of Paragon’s common stock, the timing and size of the public offering and the anticipated use of the net proceeds from the offering. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Paragon does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation.

(FNA) raised $125 million in an initial public offering (IPO) on Friday, October 15th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. BofA Securities and Piper Sandler acted as the underwriters for the IPO and Canaccord Genuity, JMP Securities and Needham & Company were co-managers. 4 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Paragon 28 in the last twelve months. The consensus among Wall Street equities research analysts is that investors should “buy” FNA shares.

Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. He covers everything from digital banking to car insurance and, whatever the topic, he aims to make it easy for consumers to get straight to the best deal. Felix has a postgraduate qualification in international journalism and is also a broadcast journalist.

Paragon 28 to Present at The Morgan Stanley 20th Annual Global Healthcare Conference

While we are independent, we may receive compensation from our partners for featured placement of their products or services. Although it’s a relatively new bank, Paragon has received plaudits for its competitive savings products in recent years. If you’re happy to manage your savings accounts online and are looking for cash ISAs that offer decent returns, Paragon may be worth a look. The bank has a range of savings accounts that are only available to existing customers, so if you do decide to open an account, you may find other products that are suitable for your saving needs. Paragon intends to use the net proceeds from the offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by Paragon, for working capital, capital expenditures and other general corporate purposes. Paragon may also use a portion of the net proceeds to acquire or invest in products, technologies or businesses that are complementary to its business; however, Paragon currently does not have any agreements or commitments to complete any such transactions.

A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve. We endeavour to ensure that the information on this site is current and accurate but you should call loan meaning confirm any information with the product or service provider and read the information they can provide. If you are unsure you should get independent advice before you apply for any product or commit to any plan. While the Paragon group was formed in 1985, it only launched as a full bank in 2014. Like many new kids on the banking block, Paragon is online-only.

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO. It offers UK customers a range of services, including savings accounts, mortgages and loans.

We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn’t influence our assessment of those products. Please don’t interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder.com compares a wide range of products, providers and services but we don’t provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.

Paragon 28 s CEO, Albert DaCosta, commented, The approval of this IDE study is another great example of our commitment to improve the lives of patients suffering from foot and ankle conditions, and it is an important advancement for our SMART 28ecosystem and total ankle portfolio. We are very pleased that the FDA has recognized the potential benefits of expanding access of this technology to more ankle patients, and we are excited to get this IDE study underway. 4 Wall Street research analysts have issued 12-month target prices for Paragon 28’s stock. On average, they expect the company’s share price to reach $28.20 in the next year. This suggests a possible upside of 104.9% from the stock’s current price. View analysts price targets for FNA or view top-rated stocks among Wall Street analysts.

• The consensus among Wall Street equities research analysts is that investors should “buy” FNA shares.
• Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
• Top institutional investors include BlackRock Inc. (3.75%), Braidwell LP (2.59%), State Street Corp (1.62%), Wasatch Advisors LP (1.52%), ArrowMark Colorado Holdings LLC (1.34%) and Geode Capital Management LLC (0.82%).
• The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.

Paragon will not receive any proceeds from the sale of common stock offered by the selling securityholders. Paragon 28 acquired Additive Orthopaedics in June 2021, providing the Company with the first and only FDA approved Patient Specific Total Talus replacement for treatment of avascular necrosis (AVN). With approval of the IDE to support future regulatory applications, the company’s SMART Total Talus is on the path to become the only device on the market intended for talar replacement in the setting of adjacent joint arthritis. Paragon 28 saw a increase in short interest during the month of August. As of August 15th, there was short interest totaling 974,200 shares, an increase of 15.5% from the July 31st total of 843,300 shares. Based on an average daily trading volume, of 262,100 shares, the short-interest ratio is presently 3.7 days.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks.

Based in Englewood, CO., Paragon 28, is a leading medical device company exclusively focused on the foot and ankle orthopedic market and is dedicated to improving patient lives. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, charcot foot and orthobiologics. The company designs products with both the patient and surgeon in mind, with the goal of improving outcomes, reducing ailment recurrence and complication rates, and making the procedures simpler, consistent, and reproducible. From the onset, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and instrumentation that cover a wide range of foot and ankle ailments including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flatfoot, Charcot foot and orthobiologics.

This milestone is an important achievement in the advancement of Paragon 28 s SMART 28 strategy, which targets to provide meaningful options to their surgeon customers and significantly improve patient outcomes. The IDE of the SMART Total Talus adds to the company s existing Patient Specific Total Talus offering by expanding use of the technology as an option for prospective total ankle replacement candidates. This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.

The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado. Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace.

Since gaining its banking licence in 2014, Paragon has expanded into providing a wide range of specialist financing products for landlords and businesses, as well as its consumer banking products. According to 4 analysts, the average rating for FNA stock is “Strong Buy.” The 12-month stock price forecast is $27.25, which is an increase of 98.76% from the latest price. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. The name “Paragon 28” was chosen by design — to never lose focus on our goal to advance the science of foot and ankle surgery.